To achieve the highest possible diagnostic sensitivity for Multiple Endocrine Neoplasia Type 1 (MEN1), laboratories must abandon any single‑method approach.
A workflow that pairs full‑gene sequencing of all 10 coding exons with dedicated copy‑number variant (CNV) analysis detects pathogenic changes in roughly 95% of familial MEN1 cases. Sequencing alone captures 80–90% of familial and about 65% of sporadic patients, while MLPA‑based CNV detection adds an additional 1–4%, closing the diagnostic gap left by nucleotide‑level techniques.
The hallmark of a maximally sensitive MEN1 testing workflow is the systematic combination of full coding‑region sequencing and structural variant screening. This integrated two‑tier strategy moves the detection rate to approximately 95% in familial cases and ensures neither point mutations nor large deletions/duplications are overlooked.
Why a Single Method Fails: The MEN1 Variant Spectrum
No Hotspot, No Shortcut – The Demand for Full‑Gene Sequencing
Disease‑causing MEN1 variants are scattered across all 10 coding exons with no localized mutational hotspot.
A targeted PCR assay that only interrogates a few known positions will miss the majority of causative changes.
Only complete sequencing of the coding region—by Sanger sequencing or targeted massively parallel sequencing (MPS/NGS)—can systematically identify the single‑nucleotide substitutions and small insertions/deletions that dominate the mutational landscape.
The Silent Structural Changes – Why CNV Detection Is Non‑Negotiable
Up to 4% of MEN1 patients carry gross deletions or duplications of entire exons or larger gene segments.
These structural rearrangements are invisible to conventional sequencing because they do not alter the nucleotide order; the gene copy number changes.
Without a dedicated structural screen, laboratories leave a measurable fraction of variants undetected, capping their sensitivity below the achievable maximum.
The Optimal Workflow: A Two‑Tiered Strategy
Tier 1: Full Coding‑Region Sequencing – Capturing the Majority
The first tier sequences all 10 exons of the MEN1 gene.
In familial cases this identifies a disease‑causing variant in 80–90% of patients; in isolated cases the yield is approximately 65%.
Both Sanger sequencing and NGS‑based panels are suitable, with NGS offering the advantage of multiplexing when MEN1 is part of a broader endocrine neoplasia panel.
Tier 2: MLPA‑Based CNV Analysis – Closing the Gap
Multiplex Ligation‑dependent Probe Amplification (MLPA) is the reference method for exon‑level copy‑number assessment in MEN1.
It quantitatively measures each exon’s dosage, detecting heterozygous deletions and duplications that sequencing cannot see.
Incorporating MLPA identifies an additional 1–4% of variants, lifting the overall detection rate in familial cases to approximately 95%.
Matching Platforms to Variant Types – A Practical Roadmap
Diagnostic developers must align the molecular method with the variant class they need to capture:
- Full‑gene Sanger or NGS → optimal for point mutations and small insertions/deletions.
- MLPA → optimal for exon‑level or larger deletions/duplications in a single gene like MEN1.
- Array‑CGH/SNP microarrays → can detect large CNVs genome‑wide but are less targeted and generally reserved for broader screening.
- Methylation‑specific PCR and targeted PCR are not primary tools for MEN1, as the disorder is not driven by imprinting defects or a single recurrent variant.
For MEN1, the essential tandem is sequencing + MLPA. When an NGS panel includes robust CNV‑calling algorithms, the MLPA step can act as confirmation, but a dedicated dosage assay remains the gold standard for validating copy‑number changes.
Understanding the Trade‑offs
The Cost and Workflow Complexity
A dual‑method workflow increases reagent costs, hands‑on time, and the number of interpretive steps.
Laboratories must budget for MLPA probemixes, dedicated capillary electrophoresis runs, and the bioinformatic or manual review of dosage plots.
However, the clinical value of the 4% yield increase outweighs the incremental expense in high‑stakes familial cancer testing.
Performance in Sporadic Cases
Even with combined sequencing and CNV analysis, the detection rate in isolated MEN1 cases stays around 65–70%.
A negative result cannot exclude a diagnosis; some variants may reside deep in intronic regions or be caused by mechanisms not surveyed by standard methods.
Setting appropriate expectations with ordering clinicians prevents misinterpretation of a “negative” result.
The Interpretation Burden
More comprehensive testing uncovers variants of uncertain significance (VUS).
Every additional exon or dosage probe amplifies the chance of finding a change whose clinical meaning is unclear.
A robust workflow must be paired with expert variant curation and clear reporting guidelines to avoid misleading reports.
Making the Right Choice for Your Laboratory
Your optimal MEN1 testing design depends on your primary goal and resources.
- If your primary focus is achieving the highest possible detection rate: Implement a routine combined workflow of full MEN1 sequencing and MLPA on every sample; this is the only evidence‑based path to ~95% sensitivity in familial cases.
- If your primary focus is cost‑conscious, high‑volume testing: Use a tiered reflex strategy—perform full‑gene sequencing first, and reflex to MLPA only when no pathogenic variant is found, accepting a slight reporting delay.
- If your primary focus is developing an IVD kit: Offer an integrated package that includes sequencing reagents and a validated MEN1‑specific MLPA probemix, enabling laboratories to run both tiers seamlessly.
- If your primary focus is sporadic MEN1 diagnosis: Adopt the same comprehensive workflow but proactively communicate that detection may be modest (~65%), reinforcing the need for clinical correlation.
By embracing a two‑tiered, sequencing‑plus‑CNV strategy, your laboratory delivers the most definitive MEN1 analysis currently possible—leaving no clinically addressable variant class behind.
Summary Table:
| Tier / Strategy | Target Variant Class | Familial Yield | Key Role & Considerations |
|---|---|---|---|
| Tier 1: Sequencing | Point mutations & small indels | 80–90% | Covers all 10 coding exons via NGS or Sanger; misses gross structural changes. |
| Tier 2: MLPA Analysis | Exon-level deletions & duplications | +1–4% | Quantifies copy-number variations (CNVs) invisible to standard sequencing. |
| Combined Workflow | All variant types (SNVs, Indels, CNVs) | ~95% | Delivers maximum diagnostic sensitivity; highly recommended for familial cases. |
Building a high-sensitivity molecular assay requires reliable components and expert guidance. CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to premium IVD raw materials, technical services, and consulting—covering every stage from concept to clinic. Elevate your testing workflows and optimize kit development with our tailored solutions. Contact us today to discuss how CamelBio can support your lab's goals!